scholarly journals Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults

2016 ◽  
Vol 10 (6) ◽  
pp. e0004753 ◽  
Author(s):  
Wilfredo R. Matias ◽  
Brie Falkard ◽  
Richelle C. Charles ◽  
Leslie M. Mayo-Smith ◽  
Jessica E. Teng ◽  
...  
AIDS ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Eduardo L.V. Silveira ◽  
Jung Joo Hong ◽  
Praveen K. Amancha ◽  
Kenneth A. Rogers ◽  
Aftab A. Ansari ◽  
...  

1990 ◽  
pp. 353-354
Author(s):  
A Kantele ◽  
H Arvilommi ◽  
A Ratilainen ◽  
L Rintala ◽  
J M Kantele ◽  
...  

Author(s):  
Aklima Akter ◽  
Meagan Kelly ◽  
Richelle C. Charles ◽  
Jason B. Harris ◽  
Stephen B. Calderwood ◽  
...  

Oral cholera vaccination protects against cholera; however, responses in young children are low and of short duration. The best current correlates of protection against cholera target Vibrio cholerae O-specific polysaccharide (anti-OSP), including vibriocidal responses. A cholera conjugate vaccine has been developed that induces anti-OSP immune responses, including memory B-cell responses. To address whether cholera conjugate vaccine would boost immune responses following oral cholera vaccination, we immunized mice with oral cholera vaccine Inaba CVD 103-HgR or buffer only (placebo) on day 0, followed by parenteral boosting immunizations on days 14, 42, and 70 with cholera conjugate vaccine Inaba OSP: recombinant tetanus toxoid heavy chain fragment or PBS/placebo. Compared with responses in mice immunized with oral vaccine alone or intramuscular cholera conjugate vaccine alone, mice receiving combination vaccination developed significantly higher vibriocidal, IgM OSP-specific serum responses and OSP-specific IgM memory B-cell responses. A combined vaccination approach, which includes oral cholera vaccination followed by parenteral cholera conjugate vaccine boosting, results in increased immune responses that have been associated with protection against cholera. These results suggest that such an approach should be evaluated in humans.


1999 ◽  
Vol 67 (2) ◽  
pp. 539-545 ◽  
Author(s):  
Jorge A. Benítez ◽  
Luis García ◽  
Anisia Silva ◽  
Hilda García ◽  
Rafael Fando ◽  
...  

ABSTRACT Vibrio cholerae 638 (El Tor, Ogawa), a new CTXΦ-negative hemagglutinin/protease-defective strain that is a cholera vaccine candidate, was examined for safety and immunogenicity in healthy adult volunteers. In a double-blind placebo-controlled study, no significant adverse reactions were observed in volunteers ingesting strain 638. Four volunteers of 42 who ingested strain 638 and 1 of 14 who received placebo experienced loose stools. The strain strongly colonized the human small bowel, as evidenced by its isolation from the stools of 37 of 42 volunteers. V. cholerae 638, at doses ranging from 4 × 107 to 2 × 109 vibrios, elicited significant serum vibriocidal antibody and anti-Ogawa immunoglobulin A antibody secreting cell responses.


2013 ◽  
Vol 20 (10) ◽  
pp. 1592-1598 ◽  
Author(s):  
Atiqur Rahman ◽  
Rasheduzzaman Rashu ◽  
Taufiqur Rahman Bhuiyan ◽  
Fahima Chowdhury ◽  
Ashraful Islam Khan ◽  
...  

ABSTRACTInfection withVibrio choleraeand oral cholera vaccines (OCVs) induce transient circulating plasmablast responses that peak within approximately 7 days after infection or vaccination. We previously demonstrated that plasmablast responses strongly correlate with subsequent levels ofV. cholerae-specific duodenal antibodies up to 6 months afterV. choleraeinfection. Hence, plasmablast responses provide an early window into the immunologic memory at the mucosal surface. In this study, we characterized plasmablast responses followingV. choleraeinfection using a flow cytometrically defined population and comparedV. cholerae-specific responses in adult patients withV. choleraeO1 infection and vaccinees who received the OCV Dukoral (Crucell Vaccines Canada). Among flow cytometrically sorted populations of gut-homing plasmablasts, almost 50% of the cells recognized either cholera toxin B subunit (CtxB) orV. choleraeO1 lipopolysaccharide (LPS). Using a traditional enzyme-linked immunosorbent spot assay (ELISPOT), we found that infection withV. choleraeO1 and OCVs induce similar responses to the protein antigen CtxB, but responses to LPS were diminished after OCV compared to those after naturalV. choleraeinfection. A second dose of OCV on day 14 failed to boost circulatingV. cholerae-specific plasmablast responses in Bangladeshi adults. Our results differ from those in studies from areas where cholera is not endemic, in which a second vaccination on day 14 significantly boosts plasmablast responses. Given these results, it is likely that the optimal boosting strategies for OCVs differ significantly between areas whereV. choleraeinfection is endemic and those where it is not.


Sign in / Sign up

Export Citation Format

Share Document